Palvella Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $586.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-04
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.49M, a 187.43% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$900.00K.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $292.00K.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $801.00K, a 109.14% increase year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$1.30M, a 223.81% decline from fiscal 2024.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.05M.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$1.18M.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$4.00M, a 140.55% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $586.00K 10-Q · filed 2026-08-04 | $878.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.68M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | -$900.00K 10-Q · filed 2026-05-07 | -$608.00K derived: sum of 2 quarters · filed 2026-05-07 | $193.00K derived: sum of 3 quarters · filed 2026-05-07 | $710.00K derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $292.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.09M derived: sum of 2 quarters · filed 2026-03-31 | $1.61M derived: sum of 3 quarters · filed 2026-08-04 | -$1.30M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $801.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.32M derived: sum of 2 quarters · filed 2026-08-04 | -$1.59M 10-Q · filed 2025-11-12 | -$1.95M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $517.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$2.39M 10-Q · filed 2026-08-04 | -$2.75M derived: sum of 3 quarters · filed 2026-08-04 | -$2.37M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | -$2.91M 10-Q · filed 2026-05-07 | -$3.27M derived: sum of 2 quarters · filed 2026-05-07 | -$2.88M derived: sum of 3 quarters · filed 2026-05-07 | -$2.15M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $25.00K derived: sum of 2 quarters · filed 2026-03-31 | $764.00K derived: sum of 3 quarters · filed 2026-03-31 | $1.05M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.12M derived: sum of 2 quarters · filed 2025-11-12 | $1.41M 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $739.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.02M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | $286.00K 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$1.18M 10-K · filed 2025-03-31 | -$2.34M 10-K · filed 2024-03-29 | |||
| 2022-12-31 | -$4.00M 10-K · filed 2024-03-29 | ||||
| 2021-12-31 | $9.88M 10-K · filed 2023-03-31 | ||||
| 2020-12-31 | -$1.66M 10-K · filed 2022-03-02 | ||||
| 2019-12-31 | -$914.00K 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | $3.25M 10-K · filed 2020-03-13 | ||||
| 2017-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$272.92K derived: sum of 2 quarters · filed 2019-03-18 | $2.87M derived: sum of 3 quarters · filed 2019-03-18 | $2.06M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $1.85M derived: sum of 2 quarters · filed 2017-11-13 | $1.05M 10-Q · filed 2017-11-13 | $1.97M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-06-30 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $2.33M 10-Q · filed 2017-08-11 | $3.26M derived: sum of 3 quarters · filed 2018-03-15 | $3.82M derived: sum of 4 quarters · filed 2018-03-15 | |
| 2017-03-31 | -$805.90K 10-Q · filed 2017-05-15 | $118.05K derived: sum of 2 quarters · filed 2018-03-15 | $676.19K derived: sum of 3 quarters · filed 2018-03-15 | $714.06K derived: sum of 4 quarters · filed 2018-03-15 | |
| 2016-12-31 | $923.96K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $1.48M derived: sum of 2 quarters · filed 2018-03-15 | $1.52M derived: sum of 3 quarters · filed 2018-03-15 | $2.06M 10-K · filed 2018-03-15 | $2.06M 10-K · filed 2017-03-30 |
| 2016-09-30 | $558.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $596.01K derived: sum of 2 quarters · filed 2017-11-13 | $1.14M 10-Q · filed 2017-11-13 | $1.50M derived: sum of 4 quarters · filed 2017-11-13 | |
| 2016-06-30 | $37.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $580.91K 10-Q · filed 2017-08-11 | $946.66K derived: sum of 3 quarters · filed 2017-08-11 | $1.11M derived: sum of 4 quarters · filed 2017-08-11 | |
| 2016-03-31 | $543.04K 10-Q · filed 2017-05-15 | $908.78K derived: sum of 2 quarters · filed 2017-05-15 | $1.07M derived: sum of 3 quarters · filed 2017-05-15 | $1.31M derived: sum of 4 quarters · filed 2017-05-15 | |
| 2015-12-31 | $365.75K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $525.82K derived: sum of 2 quarters · filed 2017-03-30 | $764.34K derived: sum of 3 quarters · filed 2017-03-30 | $556.30K 10-K · filed 2017-03-30 | |
| 2015-09-30 | $160.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $398.60K derived: sum of 2 quarters · filed 2016-11-10 | $190.55K 10-Q · filed 2016-11-10 | $504.22K derived: sum of 4 quarters · filed 2016-11-10 | |
| 2015-06-30 | $238.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $30.48K 10-Q · filed 2016-08-11 | $344.16K derived: sum of 3 quarters · filed 2016-08-11 | $315.89K derived: sum of 4 quarters · filed 2016-08-11 | |
| 2015-03-31 | -$208.05K 10-Q · filed 2016-05-12 | $105.63K derived: sum of 2 quarters · filed 2016-05-12 | $77.37K derived: sum of 3 quarters · filed 2016-05-12 | $65.86K derived: sum of 4 quarters · filed 2016-05-12 | |
| 2014-12-31 | $313.68K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $285.41K derived: sum of 2 quarters · filed 2016-03-23 | $273.90K derived: sum of 3 quarters · filed 2016-03-23 | -$137.00K 10-K · filed 2016-03-23 | |
| 2014-09-30 | -$28.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$39.77K derived: sum of 2 quarters · filed 2015-11-13 | -$450.67K 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | -$11.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$422.41K 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | -$410.90K 10-Q · filed 2015-05-14 | ||||
| 2013-12-31 | -$3.85M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |